Efgartigimod Better Than Placebo at Easing gMG Symptoms: ADAPT Trial
More adults with generalized myasthenia gravis (gMG) who were treated with efgartigimod in a Phase 3 trial experienced minimal or no symptoms than did those given a placebo, an analysis of new study data reported. Other analyses from the ADAPT trial highlighted the potential benefits of efgartigimod for people who are…